Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

IPO

- PMLiVE

Is China ready for a pharmaceutical gold rush?

Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?

- PMLiVE

Chi-Med and Lilly’s cancer drug Elunate a milestone for China

Partners tap into expanding market - but have multinationals to compete with

- PMLiVE

Moderna files record $500m IPO for RNA pipeline

Could be the largest IPO for a biotech start-up

- PMLiVE

Biopharma’s Future: Made in China

The world’s second biggest pharma market is entering a new growth phase – but meeting its needs takes investment and expertise

- PMLiVE

Home-grown colorectal cancer drug approved in China

Major milestone for China's R&D-based companies

- PMLiVE

China’s BeiGene raises $903m from Hong Kong IPO

Mammoth debut might have exceeded $1bn but for market jitters

- PMLiVE

Keytruda is first I-O drug cleared for melanoma in China

Company chasing rival BMS in world's biggest market

- PMLiVE

China’s BeiGene takes PD-1 antibody into pivotal trials

Firm aims to leapfrog immunotherapy leaders in huge market

- PMLiVE

Daily Brief: Italy in turmoil, Pharma attacks Europe’s generics move and more

A rapid round up of news from pharma, biotech and healthcare

- PMLiVE

Daily Brief: Immunotherapy combos dominate ASCO, Pharma’s Brexit warning, Big data and prostate cancer

News from the frontline of pharma, biotech and healthcare

- PMLiVE

A catalyst for change

China’s plan to boost innovation and improve drug accessibility

AstraZeneca AZ

AZ pushes harder into China with new joint venture

The Anglo-Swedish group creates a new pharmaceutical business with the Chinese FIIF

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links